|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Value investor Seth Klarman disclosed in a recent 13G filing that it tendered all of its 8.7 million stake in Cascadian Therapeutics Inc. (CASC). Cascadian shareholders received a tender offer from Seattle Genetics for $10 a share at the end of January. CASC shares were trading at $3.82 at the end of December. This is […]
Seattle Genetics, Inc. today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46, ...
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...
Seattle Genetics, Inc. today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / On Wednesday, U.S. markets failed to continue on Tuesday's gains as investors worried about rising bond yields and interest rates. The Dow Jones Industrial ...
BALA CYNWYD, PA / ACCESSWIRE / February 5, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cascadian Therapeutics, Inc. ("Cascadian ...
BERWYN, Pa. , Feb. 6, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Cascadian Therapeutics, Inc. ("Cascadian Therapeutics" or the "Company") ...
Stock Monitor: Cascadian Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on Seattle Genetics, Inc. (NASDAQ: ...
NEW YORK , Feb. 1, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
Cascadian Therapeutics, Inc. (NASDAQ:CASC) is the big mid-week winner its acquisition by Seattle Genetics, Inc. (NASDAQ:SGEN). On Wednesday, January 31st, Cascadian announced that it will be acquired by Seattle Genetics. The deal will see the latter pick up the former at $10 a share, valuing Cascadian at just shy of $614 million based on current […] The post Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition appeared first on Market Exclusive.
The following statement is being issued by Levi & Korsinsky, LLP:
Shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) surged as much as 72% after agreeing to be acquired by Seattle Genetics, Inc. (NASDAQ:SGEN) for $10 per share, a 69% premium over the prior closing price. Seattle Genetics CEO Clay Siegall wrote, "This acquisition would enhance our late-stage clinical pipeline with a potentially best-in-class, orally available and highly selective TKI for patients with HER2-positive metastatic breast cancer [...] Tucatinib would complement our existing pipeline of targeted cancer therapies, provide a third late-stage opportunity for a commercial product in solid tumors and expand our global efforts in breast cancer.
Cascadian Therapeutics saw its shares absolutely skyrocket on Wednesday after it was announced that Seattle Genetics would be acquiring the company. This is far and away the top-performing stock in Wednesday’s ...
SAN DIEGO , Jan. 31, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cascadian Therapeutics, Inc. ("Cascadian") ...
Seattle Genetics, Inc. and Cascadian Therapeutics, Inc. today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics.